Core Insights - The company achieved an annual profit of 644 million yuan, two years ahead of its original plan, driven by dual engines of external licensing and product sales [1][5] - Significant breakthroughs in global expansion were made, including licensing agreements with Zenas and Prolium [1][8] Financial Performance - The latest financial report shows a revenue surge of 135% to 2.38 billion yuan (approximately 344 million USD), with a notable profit turnaround from a loss of 453 million yuan in 2024 to a profit of 644 million yuan [5] - The company's drug sales reached 1.44 billion yuan, marking a year-on-year growth of 43.4% [5] Product Development - The core revenue driver, Orelabrutinib, has expanded its indications, contributing to sustained revenue growth, and has been included in the medical insurance directory for four major indications [5][6] - Tafasitamab, another commercialized product, was approved in May 2025 and is the first CD19 monoclonal antibody for treating relapsed or refractory diffuse large B-cell lymphoma in China [6] - The company is developing a new BCL2 inhibitor, Mesutoclax, which has shown rapid progress in clinical trials and is expected to enhance treatment options for various blood cancers [6][7] Globalization Strategy - In October 2025, the company entered a significant partnership with Zenas, with a potential transaction value exceeding 2 billion USD, marking a new record for external licensing in China's small molecule autoimmune sector [8] - The collaboration focuses on expanding the application of Orelabrutinib from hematological cancers to autoimmune diseases, which presents a larger market opportunity [8] Market Position and Valuation - Despite the significant achievements, the company's H-shares are trading at about half the valuation of its A-shares, indicating potential upside as the company explores diverse revenue sources and sustainable profitability [2][4] - Investment banks, including Goldman Sachs and CITIC Securities, have rated the company as a "buy," citing three main growth drivers: ongoing commercialization of Orelabrutinib, significant overseas potential in autoimmune disease pipelines, and the gradual realization of the value of its R&D pipeline [9]